Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2016

01-08-2016 | Urologic Oncology

Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy

Authors: Heather J. Chalfin, Jen-Jane Liu, Nilay Gandhi, Zhaoyong Feng, Daniel Johnson, George J. Netto, Charles G. Drake, Noah M. Hahn, Mark P. Schoenberg, Bruce J. Trock, Andrew V. Scott, Steven M. Frank, Trinity J. Bivalacqua

Published in: Annals of Surgical Oncology | Issue 8/2016

Login to get access

Abstract

Purpose

Perioperative blood transfusion (PBT) has been inconsistently associated with adverse outcomes. Bladder cancer patients are unique as they frequently undergo neoadjuvant chemotherapy (NAC) with resulting immunosuppression, which may be exacerbated by transfusion-related immunomodulation. We examined the effect of leukoreduced PBT on oncologic outcomes and perioperative morbidity in radical cystectomy (RC) patients who received NAC, quantifying exposure with a novel dose-index variable.

Methods

The Johns Hopkins Radical Cystectomy database was queried for patients who had undergone NAC followed by RC from 2010 to 2013. Overall, 119 patients had available PBT and survival data. A multivariable Cox model evaluated risk factors, including pathologic stage, Charlson Comorbidity Index, age, race, year of surgery, surgical margin status, PBT, and preoperative hemoglobin for bladder cancer-specific survival (CSS) and overall survival (OS). Logistic regression models determined factors that were independently associated with perioperative morbidity.

Results

Median follow-up was 7.8 months (range 0.2–41.8), and during follow-up there were 25 deaths and 21 cancer deaths. PBT significantly predicted OS (hazard ratio [HR] 1.26, 95 % confidence interval [CI] 1.07–1.49; p = 0.005), CSS (HR 1.32, 95 % CI 1.11–1.57; p = 0.002), and morbidity (odds ratio [OR] 1.67, 95 % CI 1.26–2.21; p = 0.004) in univariate analyses. In multivariable models, PBT was significantly associated with morbidity (OR 1.77, 95 % CI 1.30–2.39; p = 0.0002), but not OS or CSS. Intraoperative transfusion was associated with decreased OS and CSS, and increased morbidity, whereas postoperative transfusion was only associated with increased morbidity.

Conclusions

Intraoperative blood transfusion was associated with increased perioperative morbidity and worsened OS and CSS in patients undergoing RC who had NAC. Although PBT may be life-saving in certain patients, a restrictive transfusion strategy may improve outcomes.
Literature
1.
Dresner SM, Lamb PJ, Shenfine J, et al. Prognostic significance of peri-operative blood transfusion following radical resection for oesophageal carcinoma. Eur J Surg Oncol. 2000;26:492–7CrossRefPubMed
2.
Shiba H, Ishida Y, Wakiyama S, et al. Negative impact of blood transfusion on recurrence and prognosis of hepatocellular carcinoma after hepatic resection. J Gastrointest Surg. 2009;13:1636–42CrossRefPubMed
3.
Keller SM, Groshen S, Martini N, et al. Blood transfusion and lung cancer recurrence. Cancer. 1988;62:606–10CrossRefPubMed
4.
Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med. 2011;365(26):2453–62CrossRefPubMedPubMedCentral
5.
Herbert PC, Wells G. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group [published erratum appears in N Engl J Med. 1999;340(13):1056] N Engl J Med. 1999;340(6):409–17.CrossRef
6.
Hajjar LA, Vincent JL, Galas FR, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA. 2010;304(14):1559–67CrossRefPubMed
7.
Lacroix J, Hébert PC, Hutchison JS, et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med. 2007;356(16):1609–19CrossRefPubMed
8.
8) Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding [published erratum appears in N Engl J Med. 2013;368(24):2341]. N Engl J Med. 2013;368(1):11–21.CrossRefPubMed
9.
Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014;371(15):1381–91.CrossRefPubMed
10.
Robertson CS, Hannay HJ, Yamal JM, et al: Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial. JAMA. 2014;312(1):36–47CrossRefPubMedPubMedCentral
11.
12.
13.
Busch OR, Hop WC, Hoynck van Papendrecht MA, et al. Blood transfusions and prognosis in colorectal cancer. N Engl J Med. 1993;328:1372–6CrossRefPubMed
14.
Eickhoff JH, Andersen J, Laybourn C. Perioperative blood transfusion does not promote recurrence and death after mastectomy for breast cancer. The Danish Breast Cancer Cooperative Group. Br J Surg. 1991;78:1358–61CrossRefPubMed
15.
Blumberg N. Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: a meta-analysis of unconfounded studies. Br J Surg. 1998;85:1163–4.PubMed
16.
Niegisch G, Albers P, Rabenalt R. Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC). Urol Oncol. 2014;32(7):966–74.CrossRefPubMed
17.
Morgan TM, Barocas DA, Chang SS, et al. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol. 2013;31(6):871–7CrossRefPubMed
18.
Gierth M, Aziz A, Fritsche HM, et al. The effect of intra- and postoperative allogenic blood transfusion on patients’ survival undergoing radical cystectomy for urothelial carcinoma of the bladder. World J Urol. 2014;32(6):1447–53CrossRefPubMed
19.
Kluth LA, Xylinas E, Rieken M, et al. Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. BJU Int. 2014;113(3):393–8CrossRefPubMed
20.
Linder BJ, Frank I, Cheville JC, et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol. 2013;63(5):839–45CrossRefPubMed
21.
Sadeghi N, Badalato GM, Hruby G, et al. The impact of perioperative blood transfusion on survival following radical cystectomy for urothelial carcinoma. Can J Urol. 2012;19(5):6443–9PubMed
22.
Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev. 2007;21:327–48CrossRefPubMed
23.
Marcato PD, Favaro WJ, Duran N. Cisplatin properties in a nanobiotechnological approach to cancer: a mini-review. Curr Cancer Drug Targets. 2014;14(5):458–76.CrossRefPubMed
24.
Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [published erratum appears in N Engl J Med. 2003;349(19):1880]. N Engl J Med. 2003;349(9):859–66.CrossRefPubMed
25.
Gandhi NM, Baras A, et al. Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: predicting response and assessing outcomes. Urol Oncol. 2015;33(5):204.e1-7CrossRefPubMedPubMedCentral
26.
Lannan KL, Sahler J, Spinelli SL, Phipps RP, Blumberg N. Transfusion immunomodulation: the case for leukoreduced and (perhaps) washed transfusions. Blood Cells Mol Dis. 2013;50:61–8.CrossRefPubMed
27.
Fergusson D, Khanna MP, Tinmouth A, Hebert PC. Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials. Can J Anaesth. 2004;51:417–24.CrossRefPubMed
28.
van de Watering L. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion. 2007;47:1946. author reply 7–8.CrossRefPubMed
29.
Friese RS, Sperry JL, Phelan HA, Gentilello LM. The use of leukoreduced red blood cell products is associated with fewer infectious complications in trauma patients. Am J Surg. 2008;196:56–61.CrossRefPubMed
30.
Abel EJ, Linder BJ, et al. Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? Eur Urol. 2014;66(6):1139–47.CrossRefPubMed
31.
Moschini M, Dell’Oglio P, et al. Effect of allogeneic intraoperative blood transfusion on survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: results from a single high-volume institution. Clin Genitourin Cancer. 2015;13(6):562–7.CrossRefPubMed
32.
Eldefrawy A, Soloway MS, Katkoori D, et al. Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: the likelihood of initiation and completion. Indian J Urol. 2012;28(4):424–6.CrossRefPubMedPubMedCentral
33.
34.
Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med. 2006;34(6):1608–16CrossRefPubMed
35.
Glance LG, Dick AW, Mukamel DB, et al. Association between intraoperative blood transfusion and mortality and morbidity in patients undergoing noncardiac surgery. Anesthesiology. 2011;114(2):283–92CrossRefPubMed
36.
Corwin HL, Gettinger A, Pearl RG, et al. The CRIT Study: Anemia and blood transfusion in the critically ill–current clinical practice in the United States. Crit Care Med. 2004;32(1):39–52CrossRefPubMed
37.
38.
Harrell FE, Lee KL, Mark DB. Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87CrossRefPubMed
Metadata
Title
Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy
Authors
Heather J. Chalfin
Jen-Jane Liu
Nilay Gandhi
Zhaoyong Feng
Daniel Johnson
George J. Netto
Charles G. Drake
Noah M. Hahn
Mark P. Schoenberg
Bruce J. Trock
Andrew V. Scott
Steven M. Frank
Trinity J. Bivalacqua
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 8/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5193-4

Other articles of this Issue 8/2016

Annals of Surgical Oncology 8/2016 Go to the issue

Breast Oncology

A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072

Breast Oncology

Genetic Determinants of Nipple Aspiration Fluid Yield

Breast Oncology

Same-Day Major Breast Cancer Surgery is Safe: An Analysis of Short-Term Outcomes Using NSQIP Data

Gynecologic Oncology

The Risk of Contralateral Nonsentinel Metastasis in Patients with Primary Vulvar Cancer and Unilaterally Positive Sentinel Node

Gastrointestinal Oncology

Robotic D2 Lymph Node Dissection During Distal Subtotal Gastrectomy for Gastric Cancer: Toward Procedural Standardization

Breast Oncology

Sentinel Lymph Node Biopsy: From B04 to Tumor Genomics